Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Monday, December 01, 2014 8:31:29 AM
bullish
$ALNY recent news/filings
## source: finance.yahoo.com
Tue, 25 Nov 2014 21:32:05 GMT ~ Alnylam to Webcast Presentations at Upcoming Investor Conferences
[at noodls] - 11.25.2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the ...
read full: http://www.noodls.com/view/8CE2A707E7C2BEF0A5A8C4C01792EFE066605F98
*********************************************************
Tue, 25 Nov 2014 21:00:00 GMT ~ Alnylam to Webcast Presentations at Upcoming Investor Conferences
[Business Wire] - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the 2014 Deutsche Bank BioFEST on Tuesday, December 2, 2014 at 2:15 p.m.
read full: http://finance.yahoo.com/news/alnylam-webcast-presentations-upcoming-investor-210000331.html
*********************************************************
Mon, 17 Nov 2014 22:40:02 GMT ~ Alnylam Reports Positive Initial Phase II Data on Revusiran
read full: http://finance.yahoo.com/news/alnylam-reports-positive-initial-phase-224002949.html
*********************************************************
Mon, 17 Nov 2014 22:08:29 GMT ~ Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014
[at noodls] - 11.17.2014 - New Non-Human Primate Data on ALN-PCSsc Show Clamped Knockdown of PCSK9 up to 92% and LDL-C Reductions of up to 77% with Monthly Subcutaneous Dosing Regimen; Phase 1 Study with ALN-PCSsc on ...
read full: http://www.noodls.com/view/0745AD1E2D372039E11F2D981283CAF2F40C52F7
*********************************************************
Mon, 17 Nov 2014 22:00:00 GMT ~ Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014
[Business Wire] - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its investigational RNAi therapeutic programs toward genetically validated targets in development for the treatment of cardiovascular metabolic diseases, including: ALN-PCSsc targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AC3 targeting apolipoprotein ...
read full: http://finance.yahoo.com/news/alnylam-presents-pre-clinical-data-220000218.html
*********************************************************
$ALNY charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ALNY company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ALNY/company-info
Ticker: $ALNY
OTC Market Place: Not Available
CIK code: 0001178670
Company name: Alnylam Pharmaceuticals, Inc.
Company website: http://www.alnylam.com
Incorporated In: DE, USA
$ALNY share structure
## source: otcmarkets.com
Market Value: $7,735,421,100 a/o Nov 28, 2014
Shares Outstanding: 76,931,090 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001
$ALNY extra dd links
Company name: Alnylam Pharmaceuticals, Inc.
Company website: http://www.alnylam.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ALNY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ALNY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ALNY+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/news - http://finance.yahoo.com/q/h?s=ALNY+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ALNY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ALNY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ALNY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Alnylam+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Alnylam+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Alnylam+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.alnylam.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.alnylam.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.alnylam.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ALNY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178670&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ALNY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ALNY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ALNY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ALNY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ALNY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ALNY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ALNY+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ALNY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ALNY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ALNY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ALNY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ALNY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ALNY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ALNY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ALNY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ALNY
$ALNY DD Notes ~ http://www.ddnotesmaker.com/ALNY
Recent ALNY News
- Alnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologie • Business Wire • 08/30/2024 08:03:00 PM
- Alnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für Kardiologie • Business Wire • 08/30/2024 05:10:00 PM
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress • Business Wire • 08/30/2024 10:00:00 AM
- Alnylam to Webcast Presentations at Upcoming September Investor Conferences • Business Wire • 08/28/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 12:01:25 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 09:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:07:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:10:22 PM
- Europäischer Kardiologenkongress 2024: Alnylam legt detaillierte Ergebnisse der Phase-3-Studie HELIOS-B zu Vutrisiran▼ bei ATTR-Amyloidose mit Kardiomyopathie vor • Business Wire • 08/08/2024 02:08:00 AM
- Alnylam présentera des résultats détaillés de l'étude HELIOS-B de phase 3 pour le vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie lors du congrès 2024 de la Société européenne de cardiologie • Business Wire • 08/07/2024 11:04:00 PM
- Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 • Business Wire • 08/07/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/06/2024 08:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2024 12:01:26 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:01:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 12:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:11:34 PM
- Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity • Business Wire • 08/01/2024 12:00:00 PM
- Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results • Business Wire • 07/18/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/13/2024 12:02:23 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 08:40:50 PM
- Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations • Business Wire • 06/24/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:34:56 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM